Scotiabank initiated coverage of Blueprint Medicines (BPMC) with an Outperform rating and $150 price target Stock performance has been “choppy,” but greater appreciation of the company’s $4B ...
Shares of NASDAQ BPMC opened at $87.12 on Friday. Blueprint Medicines has a 1 year low of $80.68 and a 1 year high of $121.90. The company has a debt-to-equity ratio of 1.15, a current ratio of 2. ...
Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Blueprint Medicines (LSE:0HOJ) with a Sector Outperform recommendation. As of March 4, 2025, the average one-year price ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback